Kenzo Hiroshima
Overview
Explore the profile of Kenzo Hiroshima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
227
Citations
2691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aoki Y, Arimura K, Hiroshima K, Sato Y, Kondo M, Tagaya E
J Thorac Dis
. 2025 Feb;
17(1):109-120.
PMID: 39975728
Background: CD276 is an immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting CD276 have been tested against various cancers. However, the precise role of CD276 in mesothelioma subtypes is unknown....
2.
Jibiki N, Nakazawa T, Nogami M, Yoshida K, Hasegawa A, Guo F, et al.
Cancer Diagn Progn
. 2024 May;
4(3):326-332.
PMID: 38707735
Background/aim: HER2-positive breast carcinomas (BCs) generally behave more aggressively and show higher cytological and histological grade than HER2-negative BCs. However, the clinical properties of HER2-positive early BCs have not been...
3.
Husain A, Chapel D, Attanoos R, Beasley M, Brcic L, Butnor K, et al.
Arch Pathol Lab Med
. 2024 Apr;
148(11):1251-1271.
PMID: 38586983
Context.—: Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.—: To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.—: Pathologists involved in the...
4.
Arimura K, Hiroshima K, Nagashima Y, Nakazawa T, Ogihara A, Orimo M, et al.
BMC Cancer
. 2023 Dec;
23(1):1206.
PMID: 38062416
Background: Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor; novel LAG3 immune checkpoint inhibitors (ICIs) exhibit therapeutic activity in melanoma. The role of LAG3and ICIs of LAG3 are unknown...
5.
Canberk S, Field A, Bubendorf L, Chandra A, Cree I, Engels M, et al.
J Am Soc Cytopathol
. 2023 May;
12(4):251-257.
PMID: 37156705
The International Academy of Cytology has joined with the International Agency for Research on Cancer to bring together a group of experts in lung cytopathology to develop a WHO Reporting...
6.
Furuya Y, Hiroshima K, Wakahara T, Akimoto H, Kawai S, Ota M, et al.
Mol Clin Oncol
. 2023 Apr;
18(5):36.
PMID: 37020506
Metaplastic breast carcinoma (MBC) is a heterogeneous group of invasive breast carcinomas (IBCs) characterized by the differentiation of the neoplastic epithelium toward squamous cells and/or mesenchymal-appearing elements. The present study...
7.
Schmitt F, Bubendorf L, Canberk S, Chandra A, Cree I, Engels M, et al.
Acta Cytol
. 2022 Dec;
67(1):80-91.
PMID: 36509066
The International Academy of Cytology has joined with the International Agency for Research on Cancer (IARC) to bring together a group of experts in lung cytopathology to develop a WHO...
8.
Sa-Ngiamwibool P, Hamasaki M, Kinoshita Y, Matsumoto S, Sato A, Tsujimura T, et al.
Lung Cancer
. 2022 Nov;
175:27-35.
PMID: 36442384
Objectives: BAP1, CDKN2A, and NF2 are the most frequently altered genes in pleural mesotheliomas (PM). Discriminating PM from benign mesothelial proliferation (BMP) is sometimes challenging; it is well established that...
9.
Yabuuchi Y, Hiroshima K, Oshima H, Kanazawa J, Hayashihara K, Nakagawa T, et al.
Oncol Lett
. 2022 Nov;
24(6):440.
PMID: 36420072
Mesothelioma (MIS) is defined as a preinvasive mesothelioma that forms a single layer of mild atypical mesothelial cells lining on the serosa surface of pleura. The atypical mesothelial cells present...
10.
Nakazawa T, Nagasaka T, Yoshida K, Hasegawa A, Guo F, Wu D, et al.
BMC Endocr Disord
. 2022 Aug;
22(1):204.
PMID: 35971106
Background: Immune checkpoint proteins have not been fully examined in follicular cell-derived thyroid carcinoma and medullary thyroid carcinoma (MTC). Anaplastic thyroid carcinoma (ATC) is one of the most aggressive carcinomas....